This pancreatic association was based on the identification of a PALB2 mutation by exomic sequencing and the subsequent PALB2 analysis in additional familial pancreatic cancer patients that revealed a prevalence of 3.1% [17]. This evidence concerns the gene PALB2 and familial pancreatic carcinoma.